Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIIB, multi-center, randomized, double-blind, placebo-controlled comparative study of abatacept or infliximab in combination with methotrexate in controlling disease activity in subjects with rheumatoid arthritis having an inadequate clinical response to methotrexate

Trial Profile

A phase IIIB, multi-center, randomized, double-blind, placebo-controlled comparative study of abatacept or infliximab in combination with methotrexate in controlling disease activity in subjects with rheumatoid arthritis having an inadequate clinical response to methotrexate

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2018

At a glance

  • Drugs Abatacept (Primary) ; Infliximab; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms ATTEST
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Aug 2018 Results from AMPLE and ATTEST trials published in the Clinical and Experimental Rheumatology
    • 07 Nov 2012 Planned number of patients changed from 400 to 675 as reported by European Clinical Trials Database record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top